Passing a federal law that trims drug industry profits on companies’ top products by between 15% and 25% would lead to about 2 fewer drugs (-0.5%) being introduced in the U.S. in the law’s first decade, 23 fewer (-5%) in the second, and 34 fewer (-8%), in the third, congressional budget analysts say.
That’s a slightly different outlook for the prescription drug pipeline than the Congressional Budget Office (CBO) offered three years ago when it simulated the effect of enacting H.R. 3, the House Democrats’ bill empowering the U.S. Health and Human Services (HHS) secretary to negotiate better prescription drug prices for the Medicare program; require drug manufacturers to pay a rebate back to the federal government if they increase prices faster than inflation; and cap Medicare enrollees’ out-of-pocket spending on prescription drugs at $2,000 per year.
Passing a federal law that trims drug industry profits on companies’ top products by between 15% and 25% would lead to about 2 fewer drugs (-0.5%) being introduced in the U.S. in the law’s first decade, 23 fewer (-5%) in the second, and 34 fewer (-8%), in the third, congressional budget analysts say.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
